Cargando…

A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment

Recent concerning facts of Chikungunya virus (CHIKV); a Togaviridae family alphavirus has proved this as a worldwide emerging threat which causes Chikungunya fever and devitalizing arthritis. Despite severe outbreaks and lack of antiviral drug, a mere progress has been made regarding to an epitope-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Md. Anayet, Khan, Md. Arif, Datta, Amit, Mazumder, Md. Habibul Hasan, Hossain, Mohammad Uzzal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172456/
https://www.ncbi.nlm.nih.gov/pubmed/25682054
http://dx.doi.org/10.1016/j.molimm.2014.12.013
_version_ 1783524260400070656
author Hasan, Md. Anayet
Khan, Md. Arif
Datta, Amit
Mazumder, Md. Habibul Hasan
Hossain, Mohammad Uzzal
author_facet Hasan, Md. Anayet
Khan, Md. Arif
Datta, Amit
Mazumder, Md. Habibul Hasan
Hossain, Mohammad Uzzal
author_sort Hasan, Md. Anayet
collection PubMed
description Recent concerning facts of Chikungunya virus (CHIKV); a Togaviridae family alphavirus has proved this as a worldwide emerging threat which causes Chikungunya fever and devitalizing arthritis. Despite severe outbreaks and lack of antiviral drug, a mere progress has been made regarding to an epitope-based vaccine designed for CHIKV. In this study, we aimed to design an epitope-based vaccine that can trigger a significant immune response as well as to prognosticate inhibitor that can bind with potential drug target sites by using various immunoinformatics and docking simulation tools. Initially, whole proteome of CHIKV was retrieved from database and perused to identify the most immunogenic protein. Structural properties of the selected protein were analyzed. The capacity to induce both humoral and cell-mediated immunity by T cell and B cell were checked for the selected protein. The peptide region spanning 9 amino acids from 397 to 405 and the sequence YYYELYPTM were found as the most potential B cell and T cell epitopes respectively. This peptide could interact with as many as 19 HLAs and showed high population coverage ranging from 69.50% to 84.94%. By using in silico docking techniques the epitope was further assessed for binding against HLA molecules to verify the binding cleft interaction. In addition with this, the allergenicity of the epitopes was also evaluated. In the post therapeutic strategy, three dimensional structure was predicted along with validation and verification that resulted in molecular docking study to identify the potential drug binding sites and suitable therapeutic inhibitor against targeted protein. Finally, pharmacophore study was also performed in quest of seeing potent drug activity. However, this computational epitope-based peptide vaccine designing and target site prediction against CHIKV opens up a new horizon which may be the prospective way in Chikungunya virus research; the results require validation by in vitro and in vivo experiments.
format Online
Article
Text
id pubmed-7172456
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71724562020-04-22 A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment Hasan, Md. Anayet Khan, Md. Arif Datta, Amit Mazumder, Md. Habibul Hasan Hossain, Mohammad Uzzal Mol Immunol Article Recent concerning facts of Chikungunya virus (CHIKV); a Togaviridae family alphavirus has proved this as a worldwide emerging threat which causes Chikungunya fever and devitalizing arthritis. Despite severe outbreaks and lack of antiviral drug, a mere progress has been made regarding to an epitope-based vaccine designed for CHIKV. In this study, we aimed to design an epitope-based vaccine that can trigger a significant immune response as well as to prognosticate inhibitor that can bind with potential drug target sites by using various immunoinformatics and docking simulation tools. Initially, whole proteome of CHIKV was retrieved from database and perused to identify the most immunogenic protein. Structural properties of the selected protein were analyzed. The capacity to induce both humoral and cell-mediated immunity by T cell and B cell were checked for the selected protein. The peptide region spanning 9 amino acids from 397 to 405 and the sequence YYYELYPTM were found as the most potential B cell and T cell epitopes respectively. This peptide could interact with as many as 19 HLAs and showed high population coverage ranging from 69.50% to 84.94%. By using in silico docking techniques the epitope was further assessed for binding against HLA molecules to verify the binding cleft interaction. In addition with this, the allergenicity of the epitopes was also evaluated. In the post therapeutic strategy, three dimensional structure was predicted along with validation and verification that resulted in molecular docking study to identify the potential drug binding sites and suitable therapeutic inhibitor against targeted protein. Finally, pharmacophore study was also performed in quest of seeing potent drug activity. However, this computational epitope-based peptide vaccine designing and target site prediction against CHIKV opens up a new horizon which may be the prospective way in Chikungunya virus research; the results require validation by in vitro and in vivo experiments. Elsevier Ltd. 2015-05 2015-02-13 /pmc/articles/PMC7172456/ /pubmed/25682054 http://dx.doi.org/10.1016/j.molimm.2014.12.013 Text en Copyright © 2014 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hasan, Md. Anayet
Khan, Md. Arif
Datta, Amit
Mazumder, Md. Habibul Hasan
Hossain, Mohammad Uzzal
A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment
title A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment
title_full A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment
title_fullStr A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment
title_full_unstemmed A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment
title_short A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment
title_sort comprehensive immunoinformatics and target site study revealed the corner-stone toward chikungunya virus treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172456/
https://www.ncbi.nlm.nih.gov/pubmed/25682054
http://dx.doi.org/10.1016/j.molimm.2014.12.013
work_keys_str_mv AT hasanmdanayet acomprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT khanmdarif acomprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT dattaamit acomprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT mazumdermdhabibulhasan acomprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT hossainmohammaduzzal acomprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT hasanmdanayet comprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT khanmdarif comprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT dattaamit comprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT mazumdermdhabibulhasan comprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment
AT hossainmohammaduzzal comprehensiveimmunoinformaticsandtargetsitestudyrevealedthecornerstonetowardchikungunyavirustreatment